公开(公告)号：US20170184595A1

公开(公告)日：2017-06-29

申请号：US15312252

申请日：2015-05-21

Applicant: Medizinische Universität Wien

Inventor： Maria SIBILIA

IPC: G01N33/574

CPC classification number: G01N33/57419 ,  G01N33/57438 ,  G01N2333/71 ,  G01N2800/50 ,  G01N2800/7095

Abstract: The present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, wherein the subject has been diagnosed or suspected of suffering from inflammation-associated. These methods comprise determining the level of expression of EGFR in myeloid cells in a sample from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible to the treatment with an EGFR inhibitor/antagonist. The invention also relates to EGFR inhibitors/antagonists for use in the treatment or amelioration of inflammation-associated cancer. The invention furthermore provides in vitro methods of prognosing the survival time, progression-free survival time or disease course of a subject that has been diagnosed or suspected of suffering from from inflammation-associated cancer. In addition thereto, the invention relates to in vitro diagnostic methods of assessing the proneness of a subject to develop inflammation-associated cancer in which the expression of EGFR is determined in myeloid cells from the subject.